The role of teprotumumab in chronic, clinically active thyroid eye disease

PS Subramanian, RI Cho, A Kahana - Current opinion in …, 2023 - journals.lww.com

Efficacy of teprotumumab therapy in patients with long-durat... : Current Opinion in
Ophthalmology Efficacy of teprotumumab therapy in patients with long-duration thyroid eye …

被引用次数：3 相关文章所有 7 个版本

[PDF] lww.com

Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management

YY Caroline, RL Ford, ST Wester… - Indian journal of …, 2022 - journals.lww.com

Thyroid eye disease (TED) is a rare disease that can lead to decreased quality of life,
permanent disfigurement, and vision loss. Clinically, TED presents with exophthalmos …

被引用次数：17 相关文章所有 9 个版本

Teprotumumab: A Major Advance in the Treatment of Thyroid Eye Disease Management

YY Caroline, JA Keen… - Advances in …, 2022 - advancesinophthalmology.com

Early studies on the natural history of TED suggest that it follows a biphasic pattern,
classically titled ''Rundle's curve.''The initial active state is thought to last 1 to 3 years before …

被引用次数：2 相关文章所有 2 个版本

[HTML] nih.gov

[HTML][HTML] Teprotumumab's Impact on Proptosis in Long-duration Thyroid Eye Disease: A Systematic Review and Meta-analysis

NA Householder, C Ray - touchREVIEWS in Endocrinology, 2024 - pmc.ncbi.nlm.nih.gov

Background: Long-duration thyroid eye disease (TED) may present with persistent proptosis
despite the absence of inflammatory symptoms, and treatment options have been limited to …

ADVANCES IN OPHTHALMOLOGY AND OPTOMETRY

YY Caroline, JA Keen, EM Shriver - Advances in Ophthalmology …, 2022 - books.google.com

ADVANCES IN OPHTHALMOLOGY AND OPTOMETRY Page 438 Advances in Ophthalmology
and Optometry 7 (2022) 383–400 ADVANCES IN OPHTHALMOLOGY AND OPTOMETRY …